Elidel (pimecrolimus) is a prescription drug used to treat atopic dermatitis. Elidel can cause side effects that range from mild to serious. Examples include headache and cold and flu symptoms.

Elidel (pimecrolimus) is a brand-name drug that’s prescribed to treat atopic dermatitis in certain adults and children. Elidel comes as a topical cream that’s typically applied to the skin twice per ...

Dr Mark Ballard, the Medical Director of Respiratory and Dermatology Therapeutic Areas at the Novartis Pharmaceuticals Corporation answers our questions about their eczema cream Elidel. Dr Mark ...

Relief is in sight for parents driven to distraction by children itching and scratching their way through the night. New research findings show children being treated with Elidel® cream for their ...

Novartis’ Elidel (pimecrolimus) eczema treatment provides both adults and children with long-term control of their disease symptoms, according to new data from the Swiss giant. Novartis’ Elidel ...

March 11, 2005 -- The U.S. Food and Drug Administration (FDA) has warned healthcare professionals and patients via public health advisory of the potential cancer risk associated with use of ...

Dermatology leaders rallied to the defence of Novartis' Elidel (pimecrolimus), a topical cream for atopic eczema, this week during the 8th Congress of the European Society for Pediatric Dermatology in ...

June 30 (Reuters) - Canada's Valeant Pharmaceuticals International said it acquired rights to market skin medicine Elidel and Xerese in the U.S., Canada and Mexico from Sweden's Meda AB . Sign up here ...

Jan. 19, 2006 — The US Food and Drug Administration (FDA) has approved revisions to the safety labeling for 1% pimecrolimus cream ( Elidel, made by Novartis Pharmaceuticals Corporation) and tacrolimus ...

GÖTEBORG, Sweden--(BUSINESS WIRE)--Regulatory News: Meda has reached an agreement with Novartis to acquire global rights for Elidel (pimecrolimus 1% cream). Elidel is a patent protected, specialty ...

Deal will bring Meda another estimated $130 million over next 18 months and royalties of at least $120 million between 2013 and 2015. Meda outlicensed the dermatology products Elidel (pimecrolimus 1% ...